Every one of those 1 sits in a single category, regulation. Chinese biotech industry is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. US biotech industry appears in 1 tracked Healthcare story from June 24, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about US biotech industry
Every one of those 1 sits in a single category, regulation. Chinese biotech industry is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. US biotech industry appears in 1 tracked Healthcare story from June 24, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering US biotech industry. Shared-story counts are live from our verified record — not editorial picks.
China’s clinical drug trials hit a record 5,215 in 2025, with costs 50–60% lower than in the US. This surge, driven by Beijing’s biotech ambitions, is reshaping global drug development and raising national security concerns in Washington as Chinese firms gain dominance in cancer and vaccine research.
US biotech industry is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.